Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) FCF Margin (2022 - 2025)

Stoke Therapeutics has reported FCF Margin over the past 4 years, most recently at 2213.41% for Q4 2025.

  • For Q4 2025, FCF Margin fell 211063.0% year-over-year to 2213.41%; the TTM value through Dec 2025 reached 24.35%, up 26211.0%, while the annual FY2025 figure was 24.35%, 26211.0% up from the prior year.
  • FCF Margin for Q4 2025 was 2213.41% at Stoke Therapeutics, down from 286.0% in the prior quarter.
  • Over five years, FCF Margin peaked at 1073.0% in Q1 2022 and troughed at 2213.41% in Q4 2025.
  • A 4-year average of 488.05% and a median of 487.05% in 2024 define the central range for FCF Margin.
  • On a YoY basis, FCF Margin climbed as much as 66609bps in 2025 and fell as far as -211063bps in 2025.
  • Year by year, FCF Margin stood at 697.12% in 2022, then dropped by -7bps to 745.11% in 2023, then surged by 86bps to 102.78% in 2024, then tumbled by -2054bps to 2213.41% in 2025.
  • Business Quant data shows FCF Margin for STOK at 2213.41% in Q4 2025, 286.0% in Q3 2025, and 184.16% in Q2 2025.